NCT01803074

Study to Evaluate a HIV Drug for the Treatment of HIV Infection

Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of BMS-955176 (Double-Blinded) and BMS-955176 With Atazanavir +/- Ritonavir (Open-Labeled) in HIV-1 Infected Subjects

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 107 (actual)
• Sponsor: ViiV Healthcare · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

The primary purpose of this study is to study the safety and tolerability of a HIV drug and to evaluate a decrease of HIV-1 virus level in blood after treatments in HIV-1 infected patients

Detailed description

Masking: Open-Part B. Double Blind-Parts A and C Gender: Both female and male participants for Parts A and C. Male participants for Part B. HIV = Human Immunodeficiency Virus RNA = Ribonucleic acid

Conditions

• Infection, Human Immunodeficiency Virus
• HIV Infections

Interventions

Type	Name	Description
DRUG	BMS-955176	BMS-955176
DRUG	Placebo matching with BMS-955176	Placebo matching with BMS-955176
DRUG	Atazanavir	Atazanavir
DRUG	Ritonavir	Ritonavir
DRUG	Tenofovir	Tenofovir
DRUG	Emtricitabine	Emtricitabine

Timeline

• Start date: 2013-04-04
• Primary completion: 2014-11-29
• Completion: 2014-11-29
• First posted: 2013-03-04
• Last updated: 2019-11-25
• Results posted: 2019-11-25

Locations

1 site across 1 country: Germany